Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer
暂无分享,去创建一个
T. Uenishi | K. Hirohashi | T. Shuto | Takatsugu Yamamoto | S. Kubo | H. Tanaka | S. Nishiguchi | T. Yamamoto | T. Yamamoto | Shoji Kubo | Hiroaki Tanaka | Shuhei Nishiguchi
[1] Jia-qing Li,et al. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. , 2002, International journal of oncology.
[2] C. Rodríguez,et al. Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2002, Cancer.
[3] M. Zoli,et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience) , 2002, American Journal of Gastroenterology.
[4] H. Kinoshita,et al. Clinicopathological factors predicting outcome after resection of mass‐forming intrahepatic cholangiocarcinoma , 2001, The British journal of surgery.
[5] Yasufumi Yamaji,et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21‐1) in human lung cancer cell lines , 2001, International journal of cancer.
[6] I. Doweck,et al. The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease , 2000, British Journal of Cancer.
[7] A. Heinecke,et al. CYFRA 21-1 serum analysis in patients with esophageal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] K. Chayama,et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis , 2000, Cancer.
[9] T. Uenishi,et al. Surgery for mixed hepatocellular and cholangiocellular carcinoma. , 2000, Hepato-gastroenterology.
[10] S. Kawasaki,et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. , 2000, Surgery.
[11] N. Chalasani,et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case‐control study , 2000, Hepatology.
[12] J. Ferlay,et al. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18–29 (1999). , 1999, International journal of cancer.
[13] A. Espasa,et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. , 1999, Clinical chemistry.
[14] J. Ferlay,et al. Estimates of the worldwide mortality from 25 cancers in 1990 , 1999, International journal of cancer.
[15] W. Kwun,et al. Intrahepatic cholangiocarcinoma in Korea. , 1999, Journal of hepato-biliary-pancreatic surgery.
[16] J. Olsen,et al. Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark , 1998, Hepatology.
[17] D. Klimstra,et al. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma , 1998, The British journal of surgery.
[18] Tomomi Sato,et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level , 1998, Journal of Gastroenterology.
[19] K. Takasaki,et al. Minute nodular intrahepatic cholangiocarcinoma , 1998, Cancer.
[20] T. Peretz,et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21‐1, and carcinoembryonic antigen in nonsmall cell lung carcinoma , 1998, Cancer.
[21] C. Metz,et al. Maximum likelihood estimation of receiver operating characteristic (ROC) curves from continuously-distributed data. , 1998, Statistics in medicine.
[22] Richard A. Szucs,et al. TNM Classification of Malignant Tumors. 5th ed , 1998 .
[23] A. Bergquist,et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case‐control study , 1998, Hepatology.
[24] C A Roe,et al. Statistical Comparison of Two ROC-curve Estimates Obtained from Partially-paired Datasets , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[25] S. Chevret,et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. , 1997, European journal of cancer.
[26] M. Tsuneyoshi,et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma , 1996, Cancer.
[27] Hai-rim Shin,et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. , 1996, International journal of epidemiology.
[28] M. Kojiro,et al. A Clinicopathological study on combined hepatocellular and cholangiocarcinoma , 1996, Journal of gastroenterology and hepatology.
[29] Y. Chung,et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. , 1996, British Journal of Cancer.
[30] N. Lai,et al. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. , 1996, Chest.
[31] J. Fujimoto,et al. Clinicopathologic spectrum of resected extraductal mass‐forming intrahepatic cholangiocarcinoma , 1995, Cancer.
[32] S. Seki,et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.
[33] G. Kenter,et al. Clinical value of pretreatment serum Cyfra 21–1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer , 1995, Cancer.
[34] F. Izzo,et al. Identification and Screening of 416 Patients with Chronic Hepatitis at High Risk to Develop Hepatocellular Cancer , 1995, Annals of surgery.
[35] M. Tsuneyoshi,et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. , 1995, Human pathology.
[36] H. Kinoshita,et al. Hepatolithiasis associated with cholangiocarcinoma , 1995, World Journal of Surgery.
[37] Roger Williams,et al. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. , 1995, Gastroenterology.
[38] O. Yokosuka,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.
[39] M. Fukuoka,et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. , 1994, British Journal of Cancer.
[40] H. Kato,et al. Clinical Usefulness of CYFRA Assay in Diagnosing Lung Cancer: Measurement of Serum Cytokeratin Fragment , 1994, Japanese journal of cancer research : Gann.
[41] Yuan‐Jen Wang,et al. Clinical experience in 126 patients with tissue‐proved proximal cholangiocarcinoma , 1994, Journal of gastroenterology and hepatology.
[42] B. G. Blijenberg,et al. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. , 1994, British Journal of Cancer.
[43] Kenzo Kobayashi,et al. Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .
[44] G. Gores,et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. , 1993, Mayo Clinic proceedings.
[45] H Dienemann,et al. CYFRA 21‐1: A new marker in lung cancer , 1993, Cancer.
[46] Masakazu Yamamoto,et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular‐cholangiocarcinoma) in Japan , 1993, Cancer.
[47] K. Chayama,et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.
[48] Y. Kawarada,et al. Diagnosis and treatment of cholangiocellular carcinoma of the liver. , 1990, Hepato-gastroenterology.
[49] P. Callard,et al. Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections , 1988, The Journal of pathology.
[50] R. Warnke,et al. The Diagnostic Utility of the Keratin Profiles of Hepatocellular Carcinoma and Cholangiocarcinoma , 1988, The American journal of surgical pathology.
[51] K. Weber,et al. Differential diagnosis of gastrointestinal carcinomas by using monoclonal antibodies specific for individual keratin polypeptides. , 1986, Laboratory investigation; a journal of technical methods and pathology.
[52] C. Chu,et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. , 1986, Gastroenterology.
[53] Y. Kawarada,et al. Cholangiocellular carcinoma of the liver. , 1984, American journal of surgery.
[54] Benjamin Geiger,et al. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells , 1982, Cell.
[55] Randall G. Lee,et al. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. , 1998, Annals of surgery.
[56] S. Fan,et al. Intrahepatic Cholangiocarcinoma , 1997, World Journal of Surgery.
[57] S. Fan,et al. Intrahepatic cholangiocarcinoma. Invited commentary , 1997 .
[58] W. Su,et al. A clinical study of 130 patients with biliary tract cancers and periampullary tumors. , 1996, Oncology.
[59] Shohachi Suzuki,et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma , 1996, Cancer.
[60] A. Tamori,et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. , 1994, Hepatology.
[61] J. Daurès,et al. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.
[62] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.